繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Redhill Bizerma股价因Opaganib的积极研究结果而上市前上涨

2024-08-19 19:44

07:44 AM EDT, 08/19/2024 (MT Newswires) -- Redhill Biopharma (RDHL) said Monday that it achieved positive results from multiple in vivo studies conducted by RedHill's partner, Apogee Biotechnology Corporation, supporting the potential clinical use of opaganib for the prevention and therapy of Type 2 diabetes and other obesity-related disorders.

Opaganib treatment reduced weight gain and restored glucose tolerance in an already obese high-fat diet model, the company said.

The company's share price jumped almost 23% in recent premarket activity on Monday.

Price: 0.3460, Change: +0.06, Percent Change: +19.27

風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。